We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · April 25, 2022

Sunitinib as a Second-Line Therapy in Patients With Metastatic RCC After Immune Checkpoint Inhibitor–Based Combination Therapy

ESMO Open

 

Additional Info

Disclosure statements are available on the authors' profiles:

ESMO Open
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
ESMO Open 2022 Apr 08;7(2)100463, E Grande, T Alonso-Gordoa, O Reig, E Esteban, D Castellano, X Garcia-Del-Muro, MJ Mendez, J García-Donas, M González Rodríguez, JA Arranz-Arija, P Lopez-Criado, J Molina-Cerrillo, B Mellado, C Alvarez-Fernandez, G De Velasco, MA Cuéllar-Rivas, RM Rodríguez-Alonso, JF Rodríguez-Moreno, C Suarez-Rodriguez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading